Our Mission

We believe that treatment decisions in mental health should be guided by biology, not guesswork, tradition, or sequential experimentation.

Despite decades of progress, people seeking relief from depressior often endure months of uncertainty as treatments are tried and adjusted. NeuroKaire exists to bring measurable biological context earlier into care, helping providers and patients navigate treatment decisions with greater contidence.

Recent advances in neuroscience, cellular modeling, and biological measurement now make it possible to examine treatment response in ways that were not feasible in routine care even a few years ago.

The Vision Behind NeuroKaire

NeuroKaire was founded on the belief that biological insight should play a larger role in mental health treatment decisions. This short video shares the motivation and scientific perspective behind the company.

We Transform Depression

While BrightKaire^TM is currently focused on depression care, Neurokaire's broader vision is to apply biological response assessment across additional treatments and disease areas over time.
The underlying scientific approach is designed to be extensible, enabling future diagnostics that support treatment selection in other therapeutic contexts as evidence develops. This future direction is pursued carefully, guided by scientific validation and clinical need.

Origin Story

NeuroKaire was founded by a team with deep experience in neuroscience, clinical research, and technology - brought together by the conviction that current methods leave too much suffering unexplained. Finding a better way wasn't just a scientific challenge ... it was a human one.

Our Team

NeuroKaire is led by a multidisciplinary team spanning neuroscience, medicine,
biotechnology, and data science. Our leadership brings experience from academic research,
clinical practice, and healthcare innovation.

Talia Cohen Solal, PhD

CEO & Co-Founder

Daphna Laifenfeld, PhD

CSO & Co-Founder

Issar Yazbin

Chief Product Officer

David Pattison, CPA

VP of Business Development

Gosia Jaremko, PhD, MBA

Chief Laboratory Officer

Orit Goldman, PhD

VP of Stem Cell Product

Etay Aloni

VP of Imaging

Justin Coffey, MD

CMO

Scott Gazelle, MD-PhD

Chairman

Tom Miller, MSc

Member

Daphna Laifenfeld, PhD

Member

Joshua A. Gordon, MD, PhD

Chair of Psychiatry

Maurizio Fava

Psychiatrist-in-Chief

Stephen M. Stahl, MD, PhD, DSc

Adjunct Professor

Michael Thase, MD

Professor of Psychiatry

Mark Weiser, MD

Chairman of Psychiatry

Barbara Corneo, PhD

Associate Professor

Jessica Tenebaum

Assistant Professor

Alexander Harris, MD, PhD

Associate Professor

Two ladies standing. One is looking at the camera while other is busy in work with her laptop

A doctor immersed in a laboratory, actively engaged in research

A doctor putting test tube for research.

A chemist conducting an experiment with a container, wearing safety equipment.

Our Offices

NeuroKaire operates in the US and Israel - regions with active clinical deployments, research engagement, and partnerships.

usa

78 John Miller Way, Kearny, NJ 07032, USA

israel

Yigal Alon Street 126Tel Aviv-Yafo, 6744332, Israel

Careers

We're building a team that believes in science with real human impact.

Explore open roles

male doctor in the foreground winking and smiling. In the background, a female doctor is engaged in research.

Two young ladies holding laptops inside office.

Why biology matters in depression care

For decades, antidepressant treatment has relied on obse vation over time to determine what works. NeuroKaire exists because it is now possible to bring biological insight into that decision earlier - helping treatment move forward with greater cerfidence.

The Big Idea

NeuroKaire integrates new scientific capabilities with clinical application:

Biology first - shifting treatment decisions toward urderstanding biological response. Rather than relying on outcomes observed only after medications are tried.
Reducing uncertainty - offering context providers and patients previously did not have.
Designed for real care - built to fit naturally into clinical workflows.

How It's Different

BrightKaire^TM reflects a shift in how antidepressant selection is approached. Rather than discovering whether a medication works only after it has been tried, the focus moves toward understanding likelihood of effectiveness at the biological level.

By centering treatment decisions on functional brain biology, BrightKaire™ reframes
antidepressant selection as a proactive, biologically informed decision - supporting clinical judgment with deeper biological context.

How This Approach Works

A provider orders the test as part of care. A sample is collected and analyzed In certified
laboratories. Results are returned to support treatment decisiors. Testing is conducted in
CLIA certified, CAP accredited laboratories that meet established clinical standarcs.

step 1

Get started
‍

step 2

Sample collection

step 3

Laboratory processing

step 4

Results delivered

Learn more about the science behind BrightKaire

Partners & Recognition

Our work has been recognized by funding bodies, industry partners,
and independent media. These relationships help us advance scientific
understanding and clinical trust.

Our Partners

Awards & Recognitions

NeuroKaire (formerly Genetika+) is proud to be recognized by organizations around the world for our impact on the healthcare ecosystem.